Executive Spotlights

FogPharma Announces $178 Million Series D Financing to Advance Helicon Polypeptide Therapeutics

Cambridge, MA, November 21, 2022 (Business Wire) -- FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, and PagsGroup, also participated.


Read full article here.

Recent Posts

See All
Life Science Headlines